HAYA Therapeutics raises USD 65m in Series-A-Funding
HAYA Therapeutics AG has successfully closed its Series-A-financing round of USD 65m – an important step toward its vision of reprogramming disease-causing cellular states.
Matignon Group acquires Meon Clinic AG and Meon Center AG
The Matignon Group acquires 100% of the shares of Meon Clinic AG and Meon Center AG, based in Lucerne and Meggen.
MCH Group and Bits & Pretzels establish joint venture
MCH Group and Bits & Pretzels are joining forces under the joint venture health.tech events AG and launching health.tech | global summit, a new international leading conference for digital innovations in healthcare.
Granite Bio Debuts with USD 100m of Capital
Granite Bio AG receives USD 100m in financing through the closing of a USD 30m Series A financing round led by founding investors Versant Ventures and Novartis Venture Fund and a USD 70m Series B financing round led by Forbion and Sanofi Ventures.
IonQ acquires majority stake in id Quantique
IonQ has entered into a definitive agreement with SK Telecom and id Quantique to acquire a controlling interest in id Quantique in a share-for-share transaction.
BioVersys completes its IPO at SIX Swiss Exchange
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, has completed its Initial Public at the SIX Swiss Exchange.
ATANIS Biotech completes Financing Round
ATANIS Biotech, a Swiss biotechnology company specializing in advanced allergy diagnostics, has successfully completed an oversubscribed financing round led by Spectrum Moonshot Fund and supported by experienced investors in the allergy field.
VISCHER advises Kelun-Biotech, Harbour BioMed and RTW Investments in USD 200m Series A Financing of Windward Bio
Windward Bio Group AG, a Basel-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners.
Ikerian closes Series B Financing with strategic partnership
Ikerian, a healthcare software platform company that organizes multimodal data at-scale, closes the first tranche of USD 8m Series B Financing to advance its AI platform alongside.
MegaCAD aquires Bausoft Informatik AG
MegaCAD GmbH acquires Bausoft Informatik AG, a leading Swiss software manufacturer for building engineering services.